Yuan Yin, Cheng-Juan Chen, Ru-Nan Yu, Zhi-Jian Wang, Tian-Tai Zhang, Da-Yong Zhang
Index: 10.1016/j.bmc.2018.04.005
Full Text: HTML
Janus kinases (JAKs) regulate various inflammatory and immune responses and are targets for the treatment of inflammatory and immune diseases. Here we report the discovery and optimization of 1H-pyrazolo[3,4-d]pyrimidin-4-amino as covalent JAK3 inhibitors that exploit a unique cysteine (Cys909) residue in JAK3. Our optimization study gave compound 12a, which exhibited potent JAK3 inhibitory activity (IC50 of 6.2 nM) as well as excellent JAK kinase selectivity (>60 fold). In cellular assay, 12a exhibited potent immunomodulating effect on IL-2-stimulated T cell proliferation (IC50 of 9.4 μM). Further, Compound 12a showed efficacy in delayed hypersensitivity assay. The data supports the further investigation of these compounds as novel JAKs inhibitors.
|
Development of concise two-step catalytic approach towards l...
2018-04-10 [10.1016/j.bmc.2018.04.021] |
|
Substituent effect of N-benzylated gramine derivatives that ...
2018-04-09 [10.1016/j.bmc.2018.04.019] |
|
Rational Design and Screening of Peptide-Based Inhibitors of...
2018-04-07 [10.1016/j.bmc.2018.04.018] |
|
Characterization of Protease-Activated Receptor (PAR) ligand...
2018-04-06 [10.1016/j.bmc.2018.04.016] |
|
Screening of ligands for redox-active europium using magneti...
2018-04-04 [10.1016/j.bmc.2018.04.001] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved